| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| L1R (MPXV) | Monkeypox virus (strain Zaire-96-I-16) L1R Protein, His Tag (HPLC verified) | Monkeypox virus (strain Zaire-96-I-16) | HEK293 |  | HPLCSDS-PAGE | $485.00 50ug |   | ||
| L1R (MPXV) | Monkeypox virus (Democratic Republic of the Congo) L1R Protein, His Tag (MALS verified) | Monkeypox virus (Democratic Republic of the Congo) | HEK293 |  | MALSSDS-PAGE | $465.00 50ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Sifuvirtide | FS-0101; SFT | Phase 2 Clinical | Tianjin Fusogen Pharmaceuticals Inc | HIV Infections; Acquired Immunodeficiency Syndrome | Details |
| LP-51 | LP-51 | Phase 2 Clinical | Institute Of Pathogenic Biology Chinese Academy Of Medical Sciences | HIV Infections; Sjogren's Syndrome | Details |
| PGT-121 | PGT-121 | Phase 2 Clinical | International Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And Harvard | HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity | Details |
| MPER-656 liposome vaccine | MPER-656 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung) | Phase 1 Clinical | Polymun Scientific Gmbh | HIV Infections | Details | |
| Elipovimab | GS-9722 | Phase 1 Clinical | HIV Infections | Details | |
| CPT-31 | CPT-31; CPT31-LA | Phase 1 Clinical | Navigen | Purpura, Thrombocytopenic, Idiopathic; HIV Infections | Details |
| FB-1002(Frontier Biotechnologies) | FB-1002(前沿生物) | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Coronavirus Disease 2019 (COVID-19) | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Albuvirtide | FB-006M | Approved | 艾可宁 | Mainland China | HIV Infections | Frontier Biotechnologies Inc | 2018-05-23 | Acquired Immunodeficiency Syndrome; HIV Infections | Details | |
| Enfuvirtide | T-20; R-698; DP-178 | Approved | F. Hoffmann-La Roche Ltd | Fuzeon | United States | HIV Infections | F. Hoffmann-La Roche Ltd | 2003-03-13 | HIV Infections; Acquired Immunodeficiency Syndrome; HIV Seropositivity | Details |
